With information from the latest evidence-based studies, participants should be able to:

• Describe the effects of ezetimibe plus simvastatin on atherosclerotic progression in patients with familial hypercholesterolemia 
• Recognize the association between lipoprotein(a) levels and future coronary heart disease (CHD) risk
• Delineate the relationships of plasma HDL cholesterol levels, HDL particle size, and apolipoprotein A-I with CHD risk

With information from the latest evidence-based studies, participants should be able to: 

• Describe the effects of different dyslipidemia phenotypes from childhood to adulthood and their interaction with nonlipid risk factors on markers of subclinical atherosclerosis
• Compare the usefulness of the triglyceride/high-density lipoprotein (HDL) ratio versus the total cholesterol/HDL ratio for predicting insulin resistance and cardiometabolic risk
• Access the efficacy and safety of single-pill amlodipine/atorvastatin therapy for the simultaneous treatment of hypertension and dyslipidemia in African American patients with risk of cardiovascular disease

With information from the latest evidence-based studies, participants should be able to:

• Outline the efficacy of statin therapy on the reduction in major vascular events in patients with diabetes 
• Describe the role of extreme lipoprotein(a) levels in the prediction of risk of myocardial infarction in the general population 
• Access the impact of triglyceride levels on coronary heart disease risk after an acute coronary syndrome

With information from the latest evidence-based studies, participants should be able to:

• Describe the association between subpopulations of triglyceride-rich and high-density lipoproteins adn the extent of coronary heart disease in postmenopausal women 
• Characterize the long-term benefits of bezafibrate therapy in the secondary prevention of cardiovascular events among patients with coronary heart disease and dyslipidemia 
• Delineate the impact of informing patients of their calculated coronary risk on the effectiveness of statin therapy

With information from the latest evidence-based studies, participants should be able to:

• Discuss the benefits of pravastatin therapy in women with hypercholesterolemia 
• Describe the association between socioeconomic position and inflammatory burden among different race/ethnic groups
• Identify the age-specific associations of total cholesterol with ischemic heart disease, stroke, and other vascular mortality

With information from the latest evidence-based studies, participants should be able to:

• Assess the link of Crohn's disease to atherogenesis and high-density lipoprotein (HDL)
• Outline the effects of fenofibrate and simvastatin on HDL-related biomarkers in patients with low HDL
• Describe the suppressive effects of diacylgycerol oil on postprandial hyperlipidemia in patients with insulin resistance and glucose intolerance

With information from the latest evidence-based studies, participants should be able to:

• Describe at least one potential mechanism to explain the increased morbidity and mortality observed with use of the CETP inhibitor torcetrapib 
• Relate the importance of continuation of statin treatment as a means to reduce the risk of future cardiovascular events and to underscore patient adherence 
• Discuss the association between total cholesterol levels and stroke mortality

 Click here to listen to this podcast. (Or, to download the audio file, right click on the link and choose "Save Target As".)

With information from the latest evidence-based studies, participants should be able to:

• Recognize the association between fasting TG level changes over time and CHD risk in young adults
• Identify the development of minor strokes with increased total serum cholesterol levels
• Compare the effectiveness of two statins on CRP (<2 mg/L) and LDL-C (<70 mg/dL) among patients with type 2 diabetes

Click here to listen to this podcast. (Or, to download the audio file, right click on the link and choose "Save Target As".)